ICU vs RNAZ
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 09, 2026
ICU
64.1
AI Score
VS
ICU Wins
RNAZ
41.5
AI Score
Investment Advisor Scores
RNAZ
42score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | ICU | RNAZ | Winner |
|---|---|---|---|
| Net Income | -12.15M | -24.54M | ICU |
| Operating Income | -12.18M | -24.54M | ICU |
| ROE | -116.6% | 88.6% | RNAZ |
| ROA | -85.8% | -16.2% | RNAZ |
| Total Assets | 14.16M | 151.01M | RNAZ |
| Cash | 11.98M | 8.38M | ICU |
| Current Ratio | 3.63 | 1.97 | ICU |
Relative Price Performance (Last 90 Days)
ICU 1M: -9.8%
· 3M: +11.0%
RNAZ 1M: -49.9%
· 3M: -69.3%
Current Technical Phase
ICU
MarkdownSell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 43
RNAZ
MarkdownSell / avoid
Price below a falling SMA50 (slope -19.2%), weak momentum, RSI 21
Fundamentals Snapshot
| Metric | ICU | RNAZ |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -1.3 | -5.3 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.8% | 0.0% |
| Gross Margin | 0.9% | — |
| Operating Margin | -6.2% | 0.0% |
| EPS | -1.89 | -45.84 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, ICU is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.